

For Research Use Only

Recombinant Human IFNA17 protein (rFc Tag)(HPLC verified)



Catalog Number: Eg3088

Basic Information

Species:
Human

Purity:
>90 %, SDS-PAGE
 >90 %, SEC-HPLC

Tag:
rFc Tag

Technical Specifications

Purity:
>90 %, SDS-PAGE
 >90 %, SEC-HPLC

Endotoxin Level:
<0.1 EU/μg protein, LAL method

Source:
HEK293-derived Human IFNA17 protein Cys24-Asp189 (Accession# P01571) with a rabbit IgG Fc tag at the C-terminus.

GeneID:
3451

Accession:
P01571

Predicted Molecular Mass:
45.3 kDa

SDS-PAGE:
40-47 kDa, reducing (R) conditions

Formulation:
Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.

Biological Activity

Not tested

Storage and Shipping

Storage:

It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

- Until expiry date, -20°C to -80°C as lyophilized proteins.
- 3 months, -20°C to -80°C under sterile conditions after reconstitution.

Shipping:

The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Reconstitution

Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.

Background

Interferons (IFNs) are a family of cytokines with potent antiviral, antiproliferative, and immunomodulatory properties. There is no mouse homolog for IFNA17, but mature human IFNA17 shares 58% amino acid sequence identity with chimpanzee IFNA17. Type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha-subunit) and IFNAR2 (beta-subunit). Individual IFNA subtypes are known to display unique efficacies to viral protection. IFNA17 has been shown to be potent against HIV-1 activity. Human IFNA17 is the only IFNA subtype identified with antiviral activity but a reduced ability to activate NK cells. A mutation in IFNA17, Ile184Arg, is associated with an increased risk for cervical cancer. In summary, IFNA17 is a type I interferon with unique antiviral and immunomodulatory properties. It plays a significant role in the immune response and has been implicated in the pathogenesis of certain diseases, including prostate cancer and cervical cancer.

References

1. Pestka S, et al. (1987) Annu Rev Biochem. 56:727.
2. Goeddel, D.V. et al. (1980) Nature 287:411.
3. Ortaldo, J.R. et al. (1984) PNAS 81:4926.
4. Kim, J.W. et al. (2003) Cancer Lett. 189:183.

Synonyms


IFN-alpha-17, Interferon alpha 17, Interferon alpha-17, Interferon alpha-88, Interferon alpha-I'

For technical support and original validation data for this product please contact


T: 1 (888) 4PTGLAB (1-888-478-4522) (toll free in USA), or 1(312) 455-8498 (outside USA) E: proteintech@ptglab.com W: ptglab.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data



Purity of Recombinant Human IFNA17 was determined by SDS-PAGE. The protein was resolved in an SDS-PAGE in reducing (R) and non-reducing (NR) conditions and stained using Coomassie blue.



The purity of Human IFNA17 was greater than 90% as determined by SEC-HPLC.